<DOC>
	<DOCNO>NCT01830556</DOCNO>
	<brief_summary>Primary To investigate patient relapse metastatic squamous cell carcinoma head neck whether progression free survival ( PFS ) arm cetuximab , paclitaxel carboplatin base chemotherapy markedly worse PFS arm cetuximab 5-FU , cisplatin carboplatin base chemotherapy . Secondary To compare patient relapse metastatic squamous cell carcinoma head neck follow study variable treatment arm : - Best overall response - Duration response - Time treatment failure - Overall survival - Safety</brief_summary>
	<brief_title>Randomised Phase II , Cetuximab Combination With 5FU Cisplatin Carboplatin Versus Cetuximab Combination With Paclitaxel Carboplatin Treatment Patients With Metastatic Squamous Cell Carcinoma Head Neck</brief_title>
	<detailed_description>Recurrent and/or metastatic SCCHN patient , definition patient recurrent disease and/or newly diagnose distant metastasis , although group patient heterogeneous disease characteristic , share dismal prognosis change little past 30 year . The median survival time remain around 6-8 month poor quality life . Patients resectable locoregionally recurrent SCCHN may benefit surgery . Patients recurrent SCCHN suitable curative salvage surgery re-irradiation , patient distant metastasis , usually receive CT ( Cohen EE et al . ) A number compound demonstrate single-agent activity recurrent and/or metastatic disease include cisplatin , carboplatin , methotrexate , 5-FU , bleomycin taxanes ( Scantz SP et al ) . Cisplatin one active agent identify head neck cancer , carboplatin provide alternative patient unable tolerate cisplatin . While carboplatin associate low response rate cisplatin , appear difference agent term survival Cetuximab target therapeutic agent , chimeric IgG1 monoclonal antibody specifically bind EGFR high affinity , internalise receptor prevent ligand EGF TGF-alfa interact receptor thus effectively block ligand-induced EGFR phosphorylation . In addition , cetuximab find potentiate effect chemotherapy radiotherapy experimental system . The dose cetuximab find generally safe effective several study major tumor type express EGFR . These include colorectal cancer , squamous cell carcinoma head neck non-small cell lung cancer , cetuximab give either combination study chemotherapy radiotherapy monotherapy . The main side effect cetuximab monotherapy hypersensitivity- acne-like skin reaction .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Inclusion criterion &gt; 18 year Histologically cytologically confirm SCCHN , relapse and/or metastatic Patient must life expectancy least 3 month allow adequate followup toxicity evaluation . Clinical examination 1 unidimensional lesion accord RECIST 1.1 . PS WHO 01 study entry Adequate hematological function define WBC ≥3 x 109/litre platelet ≥100 x 109/litre , ANC &gt; 1.5 x 109/litre Hb &gt; 100 g/L Adequate liver function ; bilirubin &lt; 1.5 x UNL , ALAT ASAT &lt; 3.0 UNL , alkaline phosphate &lt; 2.5 UNL . Creatinine clearance &gt; 50mL/min Written informed consent must obtain accord local Ethics committee . &gt; 75 year Nasopharyngeal cancer cancer paranasal sinuses Inability follow treatment evaluation schedule Any condition therapy investigator 's opinion may pose risk patient interfere study objective Pregnant nursing female male female childbearing potential use adequate method birthcontrol Patients active infection serious underlie medical condition , would impair ability patient receive protocol treatment Known hypersensitivity component treatment Legal incapacity Clinically significant cardiovascular disease , e.g . cardiac failure New York Heart Association class IIIIV , uncontrolled coronary artery disease , cardiomyopathy , uncontrolled arrhythmia , uncontrolled hypertension , history myocardial infarction last 12 month . Patients clinically relevant neuropathy Previously treat relapse metastatic SCCHN except radiotherapy previously treat relapse terminate &gt; 3 month start treatment . Previously treat cetuximab , cisplatin/carboplatin , 5FU taxanes locally advance SCCHN within 3 month study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>